Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | NMT1 | P30419 | 5/20 | 0.47 |
| ▸ | NMT2 | O60551 | 4/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039547 | 1.00 | GSR (0.51) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL29630424 | 0.98 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL30581338 | 0.98 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL29943324 | 0.98 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL29592035 | 0.98 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL30881181 | 0.95 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL30881170 | 0.95 | GSR (0.50) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL24141455 | 0.95 | GSR (0.53) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL30943792 | 0.95 | GSR (0.53) | GSRFOLH1NMT1NMT2DPP8 | |
| SCHEMBL29465874 | 0.95 | GSR (0.53) | GSRFOLH1NMT1NMT2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152688-A1 | A Conjugate | ULTIMOVACS AB (SE) | 2025-05-15 | — | — | US | disclosed |
| EP-4351634-A2 | A CONJUGATE | Ultimovacs AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022258794-A2 | A CONJUGATE | ULTIMOVACS AB (SE) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152688-A1 | A Conjugate | CD4, CD74, CD2 | GSR 4781/4885FOLH1 119/4885NMT1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.